202 related articles for article (PubMed ID: 9112852)
1. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board.
Van Damme P; Kane M; Meheus A
BMJ; 1997 Apr; 314(7086):1033-6. PubMed ID: 9112852
[TBL] [Abstract][Full Text] [Related]
2. From Cannes 1993 to the present.
Van Damme P; Verwimp G
Vaccine; 1998 Nov; 16 Suppl():S3-6. PubMed ID: 9915024
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B vaccination: how to reach risk groups.
François G; Hallauer J; Van Damme P
Vaccine; 2002 Nov; 21(1-2):1-4. PubMed ID: 12443655
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus: where do we stand and what is the next step for eradication?
Komatsu H
World J Gastroenterol; 2014 Jul; 20(27):8998-9016. PubMed ID: 25083074
[TBL] [Abstract][Full Text] [Related]
5. Public vaccination programmes against hepatitis B in The Netherlands: assessing whether a targeted or a universal approach is appropriate.
Houweling H; Wittevrongel CF; Verweij M; Ruitenberg EJ;
Vaccine; 2010 Nov; 28(49):7723-30. PubMed ID: 20933042
[TBL] [Abstract][Full Text] [Related]
6. A cohesive European policy for hepatitis B vaccination, are we there yet?
Lernout T; Hendrickx G; Vorsters A; Mosina L; Emiroglu N; Van Damme P
Clin Microbiol Infect; 2014 May; 20 Suppl 5():19-24. PubMed ID: 24829936
[TBL] [Abstract][Full Text] [Related]
7. [Introduction of general hepatitis B vaccination in Switzerland].
Zimmermann H; Vaudaux B; Kammerlander R
Soz Praventivmed; 1998; 43 Suppl 1():S65-8, S138-42. PubMed ID: 9833270
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001.
Van Damme P; Vorsters A
J Med Virol; 2002 Jul; 67(3):433-9. PubMed ID: 12116040
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.
Beutels P; Edmunds WJ; Antoñanzas F; De Wit GA; Evans D; Feilden R; Fendrick AM; Ginsberg GM; Glick HA; Mast E; Péchevis M; Van Doorslaer EK; van Hout BA;
Pharmacoeconomics; 2002; 20(1):1-7. PubMed ID: 11817988
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.
Holliday SM; Faulds D
Pharmacoeconomics; 1994 Feb; 5(2):141-71. PubMed ID: 10146907
[TBL] [Abstract][Full Text] [Related]
11. The worldwide impact of vaccination on the control and protection of viral hepatitis B.
Romano' L; Paladini S; Van Damme P; Zanetti AR
Dig Liver Dis; 2011 Jan; 43 Suppl 1():S2-7. PubMed ID: 21195368
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009?
Mereckiene J; Cotter S; Lopalco P; D'Ancona F; Levy-Bruhl D; Giambi C; Johansen K; Dematte L; Salmaso S; Stefanoff P; O'Flanagan D
Vaccine; 2010 Jun; 28(28):4470-7. PubMed ID: 20451643
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B: vaccination programmes in Europe--an update.
Van Damme P
Vaccine; 2001 Mar; 19(17-19):2375-9. PubMed ID: 11257363
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).
Beutels P
Health Econ; 2001 Dec; 10(8):751-74. PubMed ID: 11747055
[TBL] [Abstract][Full Text] [Related]
15. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.
Aggarwal R; Ghoshal UC; Naik SR
J Hepatol; 2003 Feb; 38(2):215-22. PubMed ID: 12547411
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the Viral Hepatitis Prevention Board--VHPB.
McCloy E; Meheus A
Vaccine; 1998 Nov; 16 Suppl():S7-10. PubMed ID: 9915025
[TBL] [Abstract][Full Text] [Related]
17. Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse.
Tyagi V; Singh SK; Sawhney A; Taneja V; Puliyel JM
Pharmacoeconomics; 2003; 21(7):497-9. PubMed ID: 12696989
[No Abstract] [Full Text] [Related]
18. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluations of hepatitis B vaccination for developing countries.
Tu HA; Woerdenbag HJ; Kane S; Riewpaiboon A; van Hulst M; Postma MJ
Expert Rev Vaccines; 2009 Jul; 8(7):907-20. PubMed ID: 19538116
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B vaccination in countries with low endemicity.
Prescrire Int; 2000 Feb; 9(45):213-9. PubMed ID: 11503803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
